Skip to main content
. 2008 Nov 14;81(2):344–352. doi: 10.1093/cvr/cvn308

Figure 6.

Figure 6

Effect of acute treatment with ABAH, a selective myeloperoxidase (MPO) inhibitor, on cardiac MPO and caspase-3 activity in ischaemic/reperfused area. ABAH, 4-aminobenzoic acid hydrazide. **P < 0.01 vs. ND + V; ##P < 0.01 vs. HC + V. n = 8/group.